3rd international Psychiatry and Addiction Masterclass (3rd iPAM®)

Primary care, Mental Health & Long-Term Care

09:00 am
01 Oct, 2025
etc.venues, Prospero House, 241 Borough High St, London SE1 1GA

3rd international Psychiatry and Addiction Masterclass (3rd iPAM®)

Primary care, Mental Health & Long-Term Care

09:00 am
01 Oct, 2025
etc.venues, Prospero House, 241 Borough High St, London SE1 1GA

Overview:

The iPAM® is a congregation for delegates to attend and share ideas of good medical practice and latest evidence-based interventions in the field of psychiatry and addiction.

The 1st iPAM ® was delivered as a virtual conference during Covid 19 pandemic on 14th and 15th November 2020 from Dubai, UAE. We had hundreds of registrations from across five continents. Approximately a hundred questions were asked and answered during the two-day sessions and on an average 90% of the attendees rated the content, session and faculty from very good to excellent.

The 2nd iPAM ® was delivered on the 15th October 2021 in Dubai, UAE as a hybrid event and our speakers presented their expert views on the current evidence around various themes related to mental health, addiction, psychological interventions, interface of mental health with physical health and emerging trends in psychiatry. It was a resounding success.

The 3rd iPAM will be successfully organised on the 1st of October 2025 in London, UK. We have excellent speakers delivering their expert views over various topics. Our faculty will be delivering their sessions from the UAE, United Kingdom, United States of America and from other GCC countries.

Who Will Attend:

Each year iPAM ® will develop new and upcoming themes which will be deemed necessary and useful for the attending delegates.

  • Doctors- Psychiatrists, GPs, Hepatologists etc.
  • Psychologists
  • Any HCP working in the field of psychiatry and addiction.
  • Nurses
  • Social workers

The programme

09:00

Introducing the 3rd international Psychiatry and Addiction Masterclass (3rd iPAM®)

Speaker:

Prof Yasir Abbasi

Chair:

Prof Cathy Montgomery

 

09:15

Hope Beyond Conventional: Experience with Ketamine for TRD (Confirmed)

Dr Baxi Sinha
Consultant Psychiatrist & Lead, Ketamine Service for TRD Deputy Medical Director (IR)
TEWV NHS Foundation Trust

This presentation captures real-world experience from the NHS in implementing Ketamine treatment for Treatment-Resistant Depression. Sharing treatment protocols, it highlights how a motivated team, working within the constraints of limited resources, established and sustains an innovative service that is making a positive difference in clinical outcomes.

09:45

Ketmaine addiction - should we be concerned?

Speaker:

Dr Arun Dhandyudham (Provisionally Confirmed)

10:15

Can we manage psychotropic induced metabolic syndrome with GLP1 medications

Speaker:

Dr Naveed Younis (Provisonally Confirmed)

 

10:45

Q&A

Q&A

10:55

TEA BREAK

TEA BREAK

11:10

AuDHD- what is behind the diagnosis

Speaker:

Dr Khurram Saddiq (Provisionally Confirmed)

Chair:

Dr Shahid Latif (Provisionally Confirmed)

11:40

Does AddicKon Present Differently in PaKents with Neurodiversity?

Dr Cyrus Abbasian
Consultant Psychiatrist
Private Digital Psychiatrist

As clinicians, we are increasingly recognising and developing competencies in identifying and managing neurodiversity-related conditions, particluarly adult ADHD and autism. Individuals with a dual diagnosis—neurodiversity co- occurring with other mental health conditions such as addictions—pose a distinct set of clinical challenges. Their addictive behaviours, whether substance-related or behavioural (e.g. problem gambling, gaming, internet use, social media, or smartphone overuse), may present atypically and often prove more resistant to conventional treatment approaches.

This presentation explores the complexities of such dual diagnosis cases, with a focus on both substance misuse and the growing recognition of behavioural addictions. It underscores the need for mental health services to adapt and provide responsive, neurodiversity-informed care pathways.

12:10

Forensic Psychiatry at the Crossroads of Addiction: Risk, Responsibility, and Recovery in Offender Populations

Speaker:

Dr Hassanien Al Taiar (Confirmed)

12:40

Q&A

Q&A

12:50

LUNCH BREAK

LUNCH BREAK

13:50

Gaming Disorder in the UK: an overview

Speaker:

Prof Henrietta Bowden-Jones (Provisionally Confirmed)

Chair:

Dr Khurram Saddiq (Provisionally Confirmed)

14:20

The Royal college of psychiatrists - the challenges of international work

Speaker:

Prof Mohammed Al Uzri (Provisionally Confirmed)

14:50

Developing addiction psychiatry training and wokforce

Speaker:

Prof Subodh Dave (Provisionally Confirmed)

15:20

Cross-sectional comparison of long-acting injectable buprenorphine and oral medication for opioid use disorder

Professor Cathy Montgomery
Professor of Psychopharmacology & Health Inequalities; Head of Institute for Health Research
Liverpool John Moores University
Devon De Silva
Innovation and Research Unit Manager
Via

Long-Acting Injectable Buprenorphine is a recent advance in the treatment of opioid use disorder which can be administered in weekly or monthly injections, allowing people with opioid use disorder to engage with daily activities without the need or daily supervised consumption. However, there is little research on the how and why this treatment may be beneficial compared to standard of care.

This talk discusses a study where we compared self-reported outcomes for people who are prescribed Long-Acting Injectable Buprenorphine compared to other medications for opioid use disorder. We used logistic regression to identify predictors of being prescribed LAIB compared to other medication for opioid use disorder, and we compared changes in self-reported physical health, mental health and quality of life over a one-year period. We contextualised the results with qualitative interviews with people with opioid use disorder and clinicians.

15:50

Q&A

Q&A

16:00

TEA BREAK

TEA BREAK

16:15

Psychedelic assisted treatments- what the future holds (TBC)

David Nutt FMedSci
Psychiatrist and Prof of Neuropsychopharmacology
Imperial College London

Speaker:

Prof David Nutt (Confirmed)

Chair:

Prof Yasir Abbasi

16:55

Closing remarks for the 3rd iPAM

Closing remarks for the 3rd iPAM

17:00

End of Conference

End of Conference

Book tickets

Ticket
Price
Quantity
Early Bird Registration Fee: (until 1st July 2025) (In Person)
£160.00 excl VAT
Limited places
0
Standard Registration Fee (In-Person)
£180.00 excl VAT
Limited places
0

Our accreditations

abpco 2021
Manchester Bee
CPD Member
Living Wage Member
Good Employment - Sponsor
Good Employment - Member
Armed Forces Covenant
Tech UK
IHSCM
FSB
Ban The Box
Stockport County
cpdgroup